DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy.

"Disclosure statement No potential conflict of interest was reported by the author(s)."

"We thank the National RNAi Core Facility at Academia Sinica in Taiwan for providing shRNA reagents and related services. This study was partially based on data from the China Medical University Hospital cancer registry. This study was supported in part by China Medical University (CMU109-MF-97), China Medical University Hospital (DMR-CELL-2103 and DMR-CELL-2102), Ministry of Science and Technology (MOST110-2628-B-039-005, MOST108-2320-B-039-045, MOST110-2314-B-039-032, Taiwan), and the Health and welfare surcharge on tobacco products, China Medical University Hospital Cancer Research Center of Excellence (MOHW110-TDU-B-212-144024). Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities Center, Office of Research and Development at China Medical University, Taichung, Taiwan, R.O.C."